Hypertension is a major risk factor of cardiovascular death in Bangladesh and worldwide. Resistant hypertension as well as uncontrolled hypertension with 3 or more antihypertensive agents is increasingly common in clinical practice.
Before diagnosing resistant hypertension, clinicians must exclude medication nonadherence and the white coat syndrome. Isolated elevation of office blood pressure despite normal home blood pressure or 24-hour ambulatory blood pressure is common during treatment with antihypertensive medications and may lead clinicians to incorrectly diagnose patients as having resistant hypertension. A recent study estimated that the prevalence of white coat syndrome (defined as office blood pressure of >140/90 mm Hg or higher but normal 24-hour ambulatory blood pressure of 130/80 mm Hg) to be as high as 30% among patients with elevated office blood pressure despite treatment with at least 3 drugs. 9 In multiple population studies, individuals with a white coat effect had fewer cardiovascular events than those with resistant hypertension and similar rates of cardiovascular events compared with patients with well controlled hypertension. 10 However, the prognosis of hypertensive patients with white coat syndrome is worse than that of the general normotensive population. 11 Continued home blood pressure or repeated ambulatory blood pressure monitoring
Introduction
According to the seventh Joint National Committee (JNC-7), resistant hypertension is defined as the inability to achieve a blood pressure lower than 140/90 mm Hg despite optimal doses of 3 or more antihypertensive drugs, including 1 diuretic. Resistant hypertension is associated with increased cardiovascular disease 3 and with emotional stress. 4 The pathogenesis of resistant hypertension is unknown but appears to be multifactorial. Epidemiological studies demonstrate that older age, obesity, impaired renal function, and diabetes mellitus are all associated with resistant hypertension. 5, 6 Patients with resistant hypertension typically have elevated systemic vascular resistance and expanded plasma volume in the presence of normal cardiac output. 7 Mechanisms underlying this abnormal hemodynamic pattern are unknown, but minor elevation in the circulating aldosterone levels and suppression of plasma renin activity have been identified in the majority of patients with resistant hypertension. insuppressible aldosterone production after sodium loading, should be performed 2 to 3 weeks after discontinuing diuretics, angiotensin converting enzyme inhibitors, and angiotensin II receptor blockers and 4 to 6 weeks after discontinuing mineralocorticoid receptor antagonists. Patients who are found to have suppressed renin levels in the presence of elevated serum aldosterone levels (>15 ng/dL) should undergo an intravenous saline suppression test (intravenous infusion of saline of 2L over4 hours) or other confirmatory tests recommended by the Endocrine Society. 23 Patients with insuppressible aldosterone levels of 10 ng/dL or more after the intravenous saline suppression test should undergo adrenal vein sampling. Patients with bilateral aldosterone overproduction should be treated with spironolactone or eplerenone. 24 Patients with a unilateral tumor should undergo surgical removal of the adenoma, which has been shown to cure hypertension in 50% to 60% of patients.
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B. Obstructive Sleep Apnea:
In contrast to primary aldosteronism, clinical trials have shown that treatment of obstructive sleep apnea with continuous positive airway pressure (CPAP) resulted in modest blood pressure reductions in patients with resistant hypertension approximating 3 to 5 mm Hg. 26 However, greater blood pressure reductions of 7 to 10 mm Hg were reported in patients with resistant hypertension who regularly adhered to the CPAP treatment.
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C. Renal Artery Stenosis:
Renal artery stenosis is another common cause of secondary hypertension, identified in 2% to 24% of patients with resistant hypertension. 20 There was no improvement in cardiovascular or renal outcomes compared with optimal medical therapy alone in atherosclerotic renal artery stenosis. Revascularization remains a treatment option for hypertension related to fibromuscular dysplasia. 27 In addition, a recent large observational study suggested revascularization was beneficial when compared with medical therapy in reducing blood pressure in patients with resistant hypertension with atherosclerotic renal artery stenosis experiencing a rapid decline in renal function. 28 However;
prospective randomized studies are needed to confirm these findings.
D. Other Causes:
Hormonal testing to exclude other endocrine forms of hypertension such as pheochromocytoma, Cushing syndrome, or thyrotoxicosis should be performed when indicated based on clinical presentation. Certain substances or drugs, including oral is advisable for patients with white coat syndrome because between 20% and 25% of these patients may develop true resistant hypertension (uncontrolled office and 24-hour blood pressure while taking > 3 or more drugs) within 3 to 6 months of follow-up.
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Nonadherence to antihypertensive medications is another cause of pseudoresistant hypertension. Adherence can be monitored with patient self-report, pill counts, or prescription refill rates. Self-report tends to overestimate adherence to antihypertensive medications by as much as 80% compared with electronic monitoring of pillboxes (which record the date and time of bottle openings). 13 Similarly, pill counts are accurate in determining adherence in only 50% to 70% of patients compared with electronic pillboxes.
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Prevalence of medication nonadherence among patients with presumed resistant hypertension was 8% to 40% in the studies using questionnaires or pharmacy refill data. 5 The prevalence of medication nonadherence was 50% to 60% when the more sensitive technique of therapeutic drug monitoring in the serum samples was used. 16 Thus, physicians caring for patients with resistant hypertension should be highly vigilant regarding medication nonadherence. Once medication nonadherence is established, every effort should be made to identify barriers to medication adherence. These barriers may include adverse effects to antihypertensive drugs, excessively complex drug regimens, financial limitations, or patient cognitive dysfunction. 17 A plan for improved adherence should be developed in partnership with each patient according to his/her specific situation.
Secondary Causes in Resistant Hypertension
Secondary hypertension is detected in 5% to 10% of all patients with hypertension. 1, 18 Obstructive sleep apnea is observed in 30% to 40% of patients with hypertension 19 and in 60% to 70% of patients with resistant hypertension. 20 Primary aldosteronism is present in 5% to 10% of all patients with hypertension and in 7% to 20% of patients with resistant hypertension.
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A. Primary Aldosteronism
Screening tests for primary aldosteronism include measuring plasma renin activity and serum aldosterone levels. These tests can be performed while patients are taking most antihypertensive drugs, but mineralocorticoid receptor antagonists and direct renin inhibitors should be stopped before these measures. However, a confirmatory assessment with an intravenous saline suppression test, to identify the presence of Thus, a thorough history of prescription and nonprescription drug use, which may interfere with the efficacy of antihypertensive medications or directly increase blood pressure, should be obtained.
Conclusion
Resistant hypertension, particularly in patients who are already prescribed 3 or more drugs. Therefore in this cases selection of blood pressure lowering agents should be based not only on the antihypertensive efficacy but also on the incremental cost, the drugs' adverse effects, and their potential cardiovascular benefits. Optimization of antihypertensive regimen should be performed prior to extensive investigation for secondary hypertension along with non-pharmacological managementsodium intake, physical activity, substance abuse etc.
